You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease

    SBC: HEPROTECH, INC.            Topic: NIAAA

    ? DESCRIPTION (provided by applicant): Alcoholic liver disease is a highly prevalent and costly condition affecting millions of people globally. Alcohol results in high morbidity and mortality an is responsible for nearly 4% of all deaths worldwide. Despite the tremendous societal and economic burden, there is no approved therapeutics for alcoholic liver disease. Instead, the standard of care ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    SBC: ADVANTAGENE, INC            Topic: NIAAA

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhosis. While fibrosis is a normal wound healing response, in excess, it can further injure tissue and activate pro-fibrotic cells, resulting in a positive feedback loop. Scar tissue is not static, ECM re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Algorithm for Free Testosterone Determination

    SBC: FUNCTION PROMOTING THERAPIES LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The measurement of testosterone levels is central to the diagnosis of androgen disorders in men and women. Circulating testosterone is bound largely to sex hormone binding globulin (SHBG) and albumin; only the unbound or free fraction is biologically active. Therefore, in conditions that affect SHBG concentrations, such as aging, obesity, and diabetes, the dete ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Compounds for Reducing Brain A-Beta Levels via Enhanced Systemic Clearance

    SBC: AKSTON BIOSCIENCES CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by progressively worsening dementia eventually leading to death. It affects over five million people in the United States and costs the healthcare system over 200 billion per year. Currently there is no available therapy for slowing, reversing or preventing the disease. There is strong evidence suggesting that AD ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Antifungal Compound Discovery from Metagenomes

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Local Lymph Node Assay with IL-18 Endpoints

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Formulation of LbL microparticle vaccine in microneedle array for intradermal del

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    Abstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel therapeutic for hematopoietic stem cell regeneration in bone marrow post my

    SBC: Minerva Biotechnologies Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): The purpose of this study is to establish in vivo proof of principle for a human therapeutic for hematopoietic stem cell regeneration in the bone marrow after myeloablation from radiation. Blood stem cells are the mostsusceptible to the effects of radiation and the most lethal. We have already demonstrated proof of principle for our therapeutic in vitro. If suc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Ubiquitin pathway inhibitors for treatment of asthma

    SBC: Progenra, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved, targeted therapies for asthma are needed. Asthma develops when T cells (CD4+) differentiate to effector T cells, which secrete cytokines that assist in the recruitment and proliferation of various i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government